|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Brain edema and intracranial hypertension in fulminant hepatic failure:Pathophysiology and management显示文摘Intracranial hypertension is a major cause of morbidity and mortality of patients suffering from fulminant hepatic failure. The etiology of this intracranial hypertension is not fully determined, and is probably multifactorial, combining a cytotoxic brain edema due to the astrocytic accumulation of glutamine, and an increase in cerebral blood volume and cerebral blood flow, in part due to inflammation, to glutamine and to toxic products of the diseased liver. Validated methods to control intracranial hypertension in fulminant hepatic failure patients mainly include mannitol, hypertonic saline, indomethacin, thiopental, and hyperventilation. However all these measures are often not sufficient in absence of liver transplantation, the only curative treatment of intracranial hypertension in fulminant hepatic failure to date. Induced moderate hypothermia seems very promising in this setting, but has to be validated by a controlled, randomized study. Artificial liver support systems have been under investigation for many decades. The bioartificial liver, based on both detoxification and swine liver cells, has shown some efficacy on reduction of intracranial pressure but did not show survival benefit in a controlled, randomized study. The Molecular Adsorbents Recirculating System has shown some efficacy in decreasing intracranial pressure in an animal model of liver failure, but has still to be evaluated in a phase Ⅲ trial. | Olivier Detry Arnaud De Roover Pierre Honoré Michel Meurisse | 2006 | World Journal of Gastroenterology2006，12，46： | 12 |
| 2 | Carcinoid tumor of the appendix: A consecutive series from 1237 appendectomies显示文摘AIM: To report the experience of the CHU Sart Tilman, University of Liège, Belgium, in the management of appendiceal carinoid tumor. METHODS: A retrospective review of 1237 appendecto- mies performed in one single centre from January 2000 to May 2004, was undertaken. Analysis of demographic data, clinical presentation, histopathology, operative re- ports and outcome was presented. RESULTS: Among the 1237 appendectomies, 5 appen- diceal carcinoid tumors were identified (0.4%) in 4 male and 1 female patients, with a mean age of 29.2 years (range: 6-82 years). Acute appendicitis was the clinical presentation for all patients. Four patients underwent open appendectomy and one a laparoscopic procedure. One patient was reoperated to complete the excision of mesoappendix. All tumors were located at the tip of the appendix with a mean diameter of 0.6 cm (range: 0.3-1.0 cm). No adjuvant therapy was performed. All patients were alive and disease-free during a mean follow-up of 33 mo. CONCLUSION: Appendiceal carcinoid tumor most of- ten presents as appendicitis. In most cases, it is found incidentally during appendectomies and its diagnosis is rarely suspected before histological examination. Appen- diceal carcinoid tumor can be managed by simple appen- dectomy and resection of the mesoappendix, if its size is ≤ 1 cm. | Vincent Tchana-Sato Olivier Detry Marc Polus Albert Thiry Bernard Detroz Sylvie Maweja Etienne Hamoir Thierry Defechereux Carla Coimbra Arnaud De Roover Michel Meurisse Pierre Honoré | 2006 | World Journal of Gastroenterology2006，12，41： | 8 |
| 3 | Liver transplantation for acute hepatic failure due to chemotherapy-induced HBV reactivation in lymphoma patients显示文摘Hepatitis B (HBV) reactivation induced by chemotherapy is problem encountered recently in the management of malignant diseases.Chemotherapy-induced HBV reactivation may ultimately lead to terminal acute liver failure.Liver transplantation (LT) currently remains the only definitive treatment option for such cases,but is generally denied to patients suffering from malignancy.Here,the authors describe 2 cases of cancer-free and HBV graft re-infection-free survival after LT performed for terminal liver failure arising from HBV reactivation induced by chemotherapy for advanced stage lymphoma.These 2 cases,and some other reports in the literature,may suggest that patients suffering from hematologic malignancies and terminal liver disease can be considered for LT if the prognosis of their hematologic malignancy is good. | Timothée Noterdaeme Luc Longrée Christian Bataille Arnaud Deroover Anne Lamproye Jean Delwaide Yves Beguin Pierre Honoré Olivier Detry | 2011 | World Journal of Gastroenterology2011，17，25： | 6 |
| 4 | Donation after cardio-circulatory death liver transplantation显示文摘The renewed interest in donation after cardio-circulatory death (DCD) started in the 1990s following the limited success of the transplant community to expand the donation after brain-death (DBD) organ supply and following the request of potential DCD families. Since then, DCD organ procurement and transplantation activities have rapidly expanded, particularly for nonvital organs, like kidneys. In liver transplantation (LT), DCD donors are a valuable organ source that helps to decrease the mortality rate on the waiting lists and to increase the availability of organs for transplantation despite a higher risk of early graft dysfunction, more frequent vascular and ischemia-type biliary lesions, higher rates of re-listing and re-transplantation and lower graft survival, which are obviously due to theinevitable warm ischemia occurring during the declaration of death and organ retrieval process. Experimental strategies intervening in both donors and recipients at different phases of the transplantation process have focused on the attenuation of ischemia-reperfusion injury and already gained encouraging results, and some of them have found their way from pre-clinical success into clinical reality. The future of DCD-LT is promising. Concerted efforts should concentrate on the identification of suitable donors (probably Maastricht category Ⅲ DCD donors), better donor and recipient matching (high risk donors to low risk recipients), use of advanced organ preservation techniques (oxygenated hypothermic machine perfusion, normothermic machine perfusion, venous systemic oxygen persufflation), and pharmacological modulation (probably a multi-factorial biologic modulation strategy) so that DCD liver allografts could be safely utilized and attain equivalent results as DBD-LT. | Hieu Le Dinh Arnaud de Roover Abdour Kaba Séverine Lauwick Jean Joris Jean Delwaide Pierre Honoré Michel Meurisse Olivier Detry | 2012 | World Journal of Gastroenterology2012，18，33： | 6 |
| 5 | Prognostic value of ^(18)F-FDG PET/CT in liver transplantation for hepatocarcinoma显示文摘AIM:To evaluate the prognostic value of pretreatment F D G p o s i t r o n e m i s s i o n t o m o g ra p h y c o m p u t e d tomography(PET-CT) in patients with hepatocarcinoma treated by liver transplantation(LT).METHODS:The authors retrospectively analyzed the data of 27 patients(mean age 58 ± 9 years) who underwent FDG PET-CT before LT for hepatocarcinoma.Mean follow-up was 26 ± 18 mo.The FDG PET/CT was performed according to a standard clinical protocol:4 MBq FDG/kg body weight,uptake 60 min,low-dose non-enhanced CT.The authors measured the SUVmax and SUVmean of the tumor and the normal liver.The tumor/liver activity ratios(RSUVmax and RSUVmean) were tested as prognostic factors and compared to the following conventional prognostic factors:MILAN,CLIP,OKUDA,TNM stage,alphafoetoprotein level,portal thrombosis,size of the largest nodule,tumor differentiation,microvascular invasion,underlying cirrhosis and liver function.RESULTS:Overall and recurrence free survivals were80.7%and 67.4%at 3 years,and 70.6%and 67.4%at 5 years,respectively.According to a multivariate Cox model,only FDG PET/CT RSUVmax predicted recurrence free survival.Even though the MILAN criteria alone were not predictive,it is worth noting that none of the patients outside the MILAN criteria and with RSUVmax<1.15 relapsed.CONCLUSION:FDG PET/CT with an RSUVmax cutoff value of 1.15 is a strong prognostic factor for recurrence and death in patients with HCC treated by LT in this retrospective series.Further prospectivestudies should test whether this metabolic index should be systematically included in the preoperative assessment. | Olivier Detry Laurence Govaerts Arnaud Deroover Morgan Vandermeulen Nicolas Meurisse Serge Malenga Noella Bletard Charles Mbendi Anne Lamproye Pierre Honoré Paul Meunier Jean Delwaide Roland Hustinx | 2015 | World Journal of Gastroenterology2015，21，10： | 5 |
| 6 | Flexible technique for multiple organ procurement in rats: a training and research tool in transplantation 显示文摘 | Millbhor D' silva Pierre Binnet Pierre Honore | 1993 | Microsurgery1993，14，5： | 1 |
| 7 | Cadaveric liver transplantation for non-acetaminophen fulminant hepatic failure:A 20-year experience显示文摘AIM: To investigate the long-term results of liver transplantation (LT) for non-acetaminophen fulminant hepatic failure (FHF). METHODS: Over a 20-year period, 29 FHF patients underwent cadaveric whole LT. Most frequent causes of FHF were hepatitis B virus and drug-related (not acetaminophen) liver failure. All surviving patients were regularly controlled at the out-patient clinic and none was lost to follow-up. Mean follow-up was 101 mo. RESULTS: One month, one-, five- and ten-year patient survival was 79%, 72%, 68% and 68%, respectively. One month, one-, five- and ten-year graft survival was 69%, 65%, 51% and 38%, respectively. Six patients needed early (< 2 mo) retransplantation, four for primary non-function, one for early acute refractory rejection because of ABO blood group incompatibility, and one for a malignant tumor found in the donor. Two patients with hepatitis B FHF developed cerebral lesions peri-transplantion: One developed irreversible and extensive brain damage leading to death, and one suffered from deep deficits leading to continuous medical care in a specialized institution. CONCLUSION: Long-term outcome of patients transplanted for non-acetaminophen FHF may be excellent. As the quality of life of these patients is also particularly good, LT for FHF is clearly justified, despite lower graft survival compared with LT for other liver diseases. | Olivier Detry Arnaud De Roover Carla Coimbra Jean Delwaide Marie-France Hans Marie Hélène Delbouille Joseé Monard Jean Joris Pierre Damas Jacques Belache Michel Meurisse Pierre Honoré | 2007 | World Journal of Gastroenterology2007，13，9： | 0 |
| 8 | 最惠国条款:Booking.com案件的法国视角显示文摘近年来最受关注的行为无疑是在线预订平台与旅店协议中最惠国条款(“MFN条款”,亦称“平价条款”)的使用。依据此类条款, | Olivier Billard & Pierre Honor e 戴健民 邓志松 | 2016 | 工商行政管理2016，0，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员